Top Pharmaceutical Stocks To Research - July 4th

Eli Lilly and Company, AbbVie, Pfizer, Merck & Co., Inc., and Thermo Fisher Scientific are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in the research, development, manufacturing, and marketing of prescription and over-the-counter medications. Investors buy these stocks to gain exposure to the pharmaceutical industry’s growth potential and to benefit from dividends or capital appreciation tied to drug approvals, patent protections, and sales performance. Like all sector investments, pharmaceutical stocks carry risks related to regulatory decisions, clinical trial outcomes, and competitive pressures. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Eli Lilly and Company stock traded up $0.32 during trading on Friday, reaching $779.60. The company had a trading volume of 1,450,772 shares, compared to its average volume of 3,664,838. The firm's 50-day simple moving average is $775.72 and its 200 day simple moving average is $799.71. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market capitalization of $738.85 billion, a PE ratio of 63.43, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Read Our Latest Research Report on LLY

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

AbbVie stock traded down $1.25 during trading on Friday, reaching $189.50. The company had a trading volume of 3,706,217 shares, compared to its average volume of 6,248,905. The firm's 50-day simple moving average is $187.30 and its 200 day simple moving average is $188.36. AbbVie has a 1-year low of $163.63 and a 1-year high of $218.66. The firm has a market capitalization of $334.73 billion, a PE ratio of 80.64, a price-to-earnings-growth ratio of 1.27 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76.

Read Our Latest Research Report on ABBV

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

PFE stock traded up $0.13 during midday trading on Friday, reaching $25.45. The stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,625,077. The company's fifty day simple moving average is $23.67 and its 200 day simple moving average is $24.84. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market cap of $144.66 billion, a price-to-earnings ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. Pfizer has a 52-week low of $20.92 and a 52-week high of $31.54.

Read Our Latest Research Report on PFE

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

MRK stock traded down $1.42 during midday trading on Friday, reaching $80.97. The stock had a trading volume of 7,734,538 shares, compared to its average volume of 13,256,132. The company's fifty day simple moving average is $79.24 and its 200 day simple moving average is $87.18. The company has a current ratio of 1.41, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69. The company has a market cap of $203.32 billion, a price-to-earnings ratio of 11.79, a price-to-earnings-growth ratio of 0.85 and a beta of 0.39. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $129.93.

Read Our Latest Research Report on MRK

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

TMO stock traded up $0.49 during midday trading on Friday, reaching $428.25. The stock had a trading volume of 1,359,321 shares, compared to its average volume of 1,971,505. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The company's fifty day simple moving average is $409.10 and its 200 day simple moving average is $480.59. The company has a market cap of $161.66 billion, a price-to-earnings ratio of 25.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77.

Read Our Latest Research Report on TMO